---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-018867"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:50:02.440151+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Onconetix appoints James Sapirstein as Executive Chairman; former Interim CEO resigns

## Summary
- Dr. Ralph Schiess resigned as Interim CEO and CSO effective Feb 24, 2025; also to leave Proteomedix AG CEO role on May 31, 2025.
- James Sapirstein, existing Board member, appointed Executive Chairman; he is also CEO of Entero Therapeutics (Nasdaq: ENTO).
- Sapirstein compensated $400/hour for up to 20 hours/week; payment contingent on company securing sufficient capital.
- Board expanded from five to six; Andrew Oakley appointed as Class II director; former CFO at Autolus, Sosei, Vectura, Actelion.

## SEC filing metadata
- accession: 0001213900-25-018867
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 5.08, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/ea0232572-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-018867
- JSON: https://secwatch.observer/filing/0001213900-25-018867.json
- Plain text: https://secwatch.observer/filing/0001213900-25-018867.txt

## Key facts
- Executive change
  Andrew Oakley was appointed as Class II director at Onconetix, Inc..
  - Action: appointed
  - Role: Class II director
  source text: On February 24, 2025, the Board approved an increase to the Board’s size from five to six members and appointed Andrew Oakley, 62, to fill the new Board seat as a Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm
- Executive change
  James Sapirstein was appointed as Executive Chairman at Onconetix, Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: On February 24, 2025, the Company’s Board of Directors (the “Board”) appointed James Sapirstein, 63, an existing member of the Board, as Executive Chairman.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm
- Executive change
  Ralph Schiess resigned as Interim Chief Executive Officer and Chief Science Officer at Onconetix, Inc..
  - Action: resigned
  - Role: Interim Chief Executive Officer and Chief Science Officer
  source text: On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.